T-Cell Immunotherapy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Modality Type (Research and Commercialized), By Therapy Type (CAR T-Cell Therapy, T Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based), By Indication Type (Lymphoma, Leukemia, Myeloma, Melanoma, Brain & Central Nervous System, Liver Cancer, and Others) and Region

T-Cell Immunotherapy Market size was valued at US$ 4,923.2 million in 2023 and is poised to grow at a CAGR of 18.2% from 2024-2030. T-cell immunotherapy is a kind of immunotherapy that makes the immune cells to b able to attack better on cancer. There are two essential kinds of T-cell immunotherapy: CAR T-cell therapy and tumor-infiltrating lymphocytes (or TIL) therapy. Both include collecting the body's immune cells, budding vast numbers of these cells in the laboratory, and then giving these cells back to the body through a needle in your vein. T-cell transfer therapy is also known as adoptive cell therapy, immune cell therapy, and immunotherapy. The growth in investment in T-cell immunotherapy methods of disease treatment can lead to the development.

Moreover, technological advancements in production processes and advances in CAR T-cell immunotherapy for solid tumors are primary factors that can boost the market. Apart from these, clinical success and approvals of Kymriah and Yescarta unlocked encouraging and new roads for inventors of cellular immunotherapies, which can also accelerate the market in the future. However, some factors, such as the absence of skilled professionals, the high investment required for therapy growth, and the absence of standard therapy procedures can restrain the market growth. The rising demand for gene editing and cell therapies, in addition to the high mortality rates and the increasing number of clinical trials, can create an opportunity for growth. Moreover, the government is focusing on awareness about health consciousness among the rising cancer patients and geriatric population, which will provide lucrative market growth.

Key Developments

• In May 2022, a clinical supply agreement was announced between Harpoon Therapeutics and F. Hoffmann-La Roche Ltd (Roche) to provide atezolizumab (Tecentriq®) for usage in the clinical development program
• In October 2021, Takeda Pharmaceutical Company Limited acquired GammaDelta Therapeutics Limited to expand its business.